UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
Date of Report: November 24, 2009
(Date of earliest event reported)
IGENE BIOTECHNOLOGY, INC.
__________________________________________________
(Exact name of registrant as specified in charter)
Maryland 000-15888 52-1230461
_________________ ________________ ___________________
(State or Other (Commission File (IRS Employer
Jurisdiction Number) Identification No.)
of Incorporation)
9110 Red Branch Road 21045
Columbia, Maryland
_____________________ _______________
(Address of principal (Zip code)
executive of offices)
(410) 997-2599
______________________________
(Registrant's telephone number
including area code)
n/a
______________________________
(Former Name or former
address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see
General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-
2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-
4(c) under the Exchange Act (17 CFR 240.13e-4(c))
____________________________________________________________
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
On November 24, 2009, the directors of IGENE
Biotechnology, Inc. (the "Company") unanimously resolved to
delete Section 11 of Article 1 of the Bylaws of the Company
and replace it with: "Informal Action by Stockholders. Any
action required or permitted to be taken at any meeting of
stockholders may be taken without a meeting if a consent in
writing setting forth such action is signed by the holders
of the requisite number of shares as provided herein and who
are entitled to vote thereon and such consent is filed with
the records of stockholders' meetings."
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned
hereunto duly authorized.
IGENE BIOTECHNOLOGY, INC.
December 1, 2009 By: /S/ STEPHEN F. HIU
_______________________________
STEPHEN F. HIU
President